Conference Correspondent

Initial Results of the Phase 2 Treatment-Naïve Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL

Conference Correspondent - ASH 2017 - CLL

Venetoclax (VEN), a once-daily oral inhibitor of BCL2, achieves high response rates and acceptable toxicity in patients with relapsed or refractory and treatment-naïve (TN) chronic lymphocytic leukemia (CLL), both as a single agent and in combination with anti-CD20 monoclonal antibodies such as obinutuzumab (OBIN), where minimal residual disease (MRD)-negative responses have been observed in the majority of patients.1 Preclinical data suggest that concurrent treatment with the Bruton tyrosine kinase inhibitor ibrutinib (IBR) may further potentiate sensitivity to VEN.2 At ASH 2017, the authors reported on the initial results from the phase 2 cohort of TN patients from a phase 1b/2 study of the combination of OBIN, IBR, and VEN in CLL.3

A total of 25 patients with TN, symptomatic CLL meeting International Working Group on CLL 2008 guideline indications for therapy were treated for 14 cycles of 28 days each with OBIN, IBR, and VEN started sequentially over the first 3 cycles. OBIN was started at cycle 1, IBR in cycle 2, and VEN in cycle 3. Baseline risk characteristics in these patients included unmutated IGHV in 17 (71%) patients, complex karyotype in 6 (24%), del(17p) in 3 (12%), del(11q) in 5 (20%), del(13q) in 5 (20%), and tri(12) in 3 (12%).

The most common grade 1/2 treatment-related adverse events (TRAEs) were infusion reactions (76%), nausea (60%), bruising (56%), oral mucositis (52%), and dyspepsia (48%). The most common grade 3/4 TRAEs were thrombocytopenia (48%), lymphopenia (44%), leukopenia (40%), hypertension (36%), and neutropenia (28%). There were no cases of neutropenic fever or tumor lysis syndrome.

Of the 25 patients who reached the first (post-cycle 8) response, 96% had an objective response, with a 52% rate of complete remission (CR), including with incomplete marrow recovery (CRi). MRD-negative status in both blood and bone marrow was achieved in 14 (58%) patients: 3 CR, 5 CRi, and 6 partial remission.

The authors concluded that the combination of OBIN, IBR, and VEN can be given safely and appears highly effective as initial therapy for CLL after response assessment. Objective responses, including MRD-negative CR, have been achieved in all patients to date. Results for the primary end point of MRD-negative CR after cycle 14 are expected in May 2018.

References

  1. Gentile M, et al. Expert Opin Investig Drugs. 2017;26:1307-1316.
  2. Jayappa KD, et al. Blood Adv. 2017;1:933-946.
  3. Rogers KA, et al. ASH 2017. Abstract 431.
Related Items
Efficacy and Safety of Bendamustine and Rituximab as First Salvage Treatment in CLL: Results of the GIMEMA-ERIC LLC1315 Study
Conference Correspondent published on December 13, 2017 in ASH 2017 - CLL
Phase 1/2 Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL
Conference Correspondent published on December 13, 2017 in ASH 2017 - CLL
Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naïve Patients with CLL: The Phase 1b/2 ACE-CL-003 Study
Conference Correspondent published on December 13, 2017 in ASH 2017 - CLL
Adverse Events, Resource Use, and Economic Burden in Patients with Mantle-Cell Lymphoma in the United States
Conference Correspondent published on December 13, 2017 in ASH 2017 - CLL
High Complete Response Rates with Pembrolizumab with Rituximab in Patients with Relapsed FL: Results of an Open-Label, Phase 2 Study
Conference Correspondent published on December 13, 2017 in ASH 2017 - CLL
Last modified: December 12, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME